The entire world is looking up to India in the backdrop of the success of its COVID-19 vaccination drive, Prime Minister Narendra Modi said on Saturday as he lauded vaccine manufacturers for playing a “big role” in the success story of the country.
Modi made the remarks during his meeting with Indian COVID-19 vaccine manufacturers who said his leadership was a key factor in India being able to administer 100 crore doses of the jabs in just about nine months.
The domestic vaccine manufacturers appreciated the vision and dynamic leadership of the prime minister in providing continuous guidance and support towards the development of the vaccines, a statement issued by the Prime Minister’s Office (PMO) said.
They also praised the never-seen-before collaboration between the government and the industry, and applauded the regulatory reforms, simplified procedures, timely approvals, and forthcoming and supportive nature of the government throughout this endeavour, the PMO said.
The vaccine manufacturers noted that had the country been following old norms, there would have been a considerable delay and “we would not have been able to reach the vaccination level that we have attained till now,” the statement said.
Prime Minister Modi praised the efforts of the vaccine manufacturers, which has resulted in the country crossing the milestone of 100 crore vaccinations, and said that they have played a big role in the success story of India.
He appreciated their hard work and confidence given by them during the pandemic, the PMO said.
The prime minister exhorted that the country needs to institutionalise the best practises learnt during the last one-and-a-half years, and said that this is an opportunity to modify our practises, in tune with the global standards.
He said that the entire world is looking up to India in the backdrop of the success of the vaccination drive.
Modi also said that the vaccine manufacturers should continuously work together to be ready to face future challenges.
The interaction was attended by Cyrus Poonawalla and Adar Poonawalla, Serum Institute of India; Dr. Krishna Ella and Suchitra Ella, Bharat Biotech International Ltd; Pankaj Patel and Shervil Patel, Zydus Cadila; Mahima Datla and Narender Mantela, Biological E. Ltd; Sanjay Singh and Satish Ramanlal Mehta, Gennova Biopharmaceuticals Ltd; Satish Reddy and Deepak Sapra, Dr. Reddy’s Lab; and Rajesh Jain and Harshit Jain, Panacea Biotec Ltd.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.